?-2,3-sialyltransferase type 3N and ?-1,3-fucosyltransferase type VII are related to sialyl Lewisx synthesis and patient survival from lung carcinoma
1997; Wiley; Volume: 79; Issue: 9 Linguagem: Inglês
10.1002/(sici)1097-0142(19970501)79
ISSN1097-0142
AutoresJun‐ichi Ogawa, Hiroshi Inoué, Shirosaku Koide,
Tópico(s)Cancer Research and Treatments
ResumoBACKGROUND Biosynthesis of sialyl Lewisx (sLex) requires a sialyltransferase for α-2,3-sialylation and a fucosyltransferase for α-1,3-fucosylation. To date, five human α-1,3-fucosyltransferase (Fuc-T) genes and five human α-2,3-sialyltransferase (ST) genes have been cloned. However, it is not known which enzyme is mainly responsible for sLex synthesis. METHODS Three hundred thirteen patients with nonsmall cell lung carcinoma who had a curative tumor resection were the subjects of this study. Using tumor tissues fixed in formaldehyde, amplification of genomic DNA of Fuc-T and ST was performed by PCR and correlated with sLex staining and patient prognosis. RESULTS The frequency of strong ST3N and Fuc-TVII amplification was significantly higher than that of STZ, ST4, Fuc-TIII, Fuc-TV, and Fuc-TVI amplification (P < 0.01). The frequency of sLex staining was similar to ST3N and Fuc-TVII amplification. Survival of the patients whose tumors had strong amplification of both ST3N and Fuc-TVII was significantly shorter than that of patients whose tumors had no amplification of either gene (P < 0.01). In a multivariate analysis of survival, Fuc-TVII remained a statistically significant prognostic factor. CONCLUSIONS In lung carcinoma, ST3N and Fuc-TVII may both be related to sLex synthesis, and Fuc-TVII is a more important indicator of poor prognosis. Cancer 1997; 79:1678-85. © 1997 American Cancer Society.
Referência(s)